Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacod…
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Estimated
~$10 – $8,750
Cogent Biosciences, Inc.NCT07383506
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal res…
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Estimated
~$10 – $1,125
Tempus AINCT07211178
Phase 1
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting tha…
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+18 more
Estimated
~$10 – $7,500
QuantumLeap Healthcare Collaborative